Treatment-naïve patients displayed higher levels of plasma IFN-α compared to SLE patients on treatment (P <0.001) and healthy controls (P <0.001) (Figure 3B) suggesting an important role of IFN-α in modulating disease activity. Here, IFNA1 is linked to systemic lupus erythematosus.